Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 27;20(1):218.
doi: 10.1186/s12874-020-01098-5.

Dynamic RMST curves for survival analysis in clinical trials

Jason J Z Liao  1 , G Frank Liu  2 , Wen-Chi Wu  2
Affiliations

Dynamic RMST curves for survival analysis in clinical trials

Jason J Z Liao et al. BMC Med Res Methodol. .

Abstract

Background: The data from immuno-oncology (IO) therapy trials often show delayed effects, cure rate, crossing hazards, or some mixture of these phenomena. Thus, the proportional hazards (PH) assumption is often violated such that the commonly used log-rank test can be very underpowered. In these trials, the conventional hazard ratio for describing the treatment effect may not be a good estimand due to the lack of an easily understandable interpretation. To overcome this challenge, restricted mean survival time (RMST) has been strongly recommended for survival analysis in clinical literature due to its independence of the PH assumption as well as a more clinically meaningful interpretation. The RMST also aligns well with the estimand associated with the analysis from the recommendation in ICH E-9 (R1), and the test/estimation coherency. Currently, the Kaplan Meier (KM) curve is commonly applied to RMST related analyses. Due to some drawbacks of the KM approach such as the limitation in extrapolating to time points beyond the follow-up time, and the large variance at time points with small numbers of events, the RMST may be hindered.

Methods: The dynamic RMST curve using a mixture model is proposed in this paper to fully enhance the RMST method for survival analysis in clinical trials. It is constructed that the RMST difference or ratio is computed over a range of values to the restriction time τ which traces out an evolving treatment effect profile over time.

Results: This new dynamic RMST curve overcomes the drawbacks from the KM approach. The good performance of this proposal is illustrated through three real examples.

Conclusions: The RMST provides a clinically meaningful and easily interpretable measure for survival clinical trials. The proposed dynamic RMST approach provides a useful tool for assessing treatment effect over different time frames for survival clinical trials. This dynamic RMST curve also allows ones for checking whether the follow-up time for a study is long enough to demonstrate a treatment difference. The prediction feature of the dynamic RMST analysis may be used for determining an appropriate time point for an interim analysis, and the data monitoring committee (DMC) can use this evaluation tool for study recommendation.

Keywords: Estimand; Immuno-oncology trial; Log-rank test; Mixture Weibull; RMST; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests

Figures

Fig. 1
Fig. 1
The screenshot of the KM survival curves for the EORTC 1684 study data [28]
Fig. 2
Fig. 2
The dynamic RMST ratio and difference curve for the re-constructed EORTC 1684 study data
Fig. 3
Fig. 3
The screenshot of the KM survival curves for the CheckMate141 OS data [32]
Fig. 4
Fig. 4
The dynamic RMST ratio and difference curve for re-constructed CheckMate141 OS data
Fig. 5
Fig. 5
The screenshot of the KM survival curves for the CheckMate 057 data [33]
Fig. 6
Fig. 6
The dynamic RMST ratio and difference curve for the re-constructed CheckMate 057 data
See this image and copyright information in PMC

References

    1. Chen TT. Statistical issues and challenges in immuno-oncology. J ImmunoTherapy Cancer. 2013;1:1–18. doi: 10.1186/2051-1426-1-18. - DOI - PMC - PubMed
    1. Callegaro A, Spiessens B. Testing treatment effect in randomized clinical trials with possible nonproportional hazards. Statistics Biopharmaceutical Research. 2017;9(2):204–211. doi: 10.1080/19466315.2016.1257436. - DOI
    1. Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, Fu H, Claggett B, Wei LJ. Interpretability of Cancer clinical trials results using restricted mean survival time as an alternative to the Hazard ratio. JAMA Oncol. 2017;3(12):1692–1696. doi: 10.1001/jamaoncol.2017.2797. - DOI - PMC - PubMed
    1. Rufibach K. Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond. Pharm Stat. 2019;18:145–65. - PubMed
    1. Huang B, Kuan P-F. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point. Pharm Stat. 2018;17:202–213. doi: 10.1002/pst.1846. - DOI - PubMed

LinkOut - more resources